CLEARSIDE BIOMEDICAL INC

CLSD10 Dec 2024
Healthcare
$1
-0.01 (-0.97%)
Lowest Today
$0.99
Highest Today
$1.03
Today’s Open
$1
Prev. Close
$1.03
52 Week High
$2.12
52 Week Low
$0.92
To Invest in CLEARSIDE BIOMEDICAL INC

CLEARSIDE BIOMEDICAL INC

Healthcare
CLSD10 Dec 2024
-0.01 (-0.97%)
1M
3M
6M
1Y
5Y
Low
$0.99
Day’s Range
High
$1.03
0.99
52 Week Low
$0.92
52-Week Range
52 Week High
$2.12
0.92
1 Day
-
1 Week
-5.6%
1 month return
-6.04%
3 month return
-11.4%
6 month return
-15.83%
1 Year return
-1.94%
3 Years return
-65.41%
5 Years return
-38.78%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
3.74
Vanguard Total Stock Mkt Idx Inv
2.6
Carmignac Gestion
2.55
Carmignac Pf L-S Eurp Eqs F EUR Acc
1.99
BlackRock Inc
1.05
Vanguard Institutional Extnd Mkt Idx Tr
1.03
Renaissance Technologies Corp
0.98

Market Status

Fundamentals
Market Cap
78.12 mln
PB Ratio
3.93
PE Ratio
0
Enterprise Value
55.31 mln
Total Assets
34.02 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Organisation
CLEARSIDE BIOMEDICAL INC
Employees
30
Industry
Biotechnology
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step